Stocktoria
HERBALIFE LTD. HLF
NYSE · stock · Wholesale-Drugs, Proprietaries & Druggists' Sundries · website · IPO 2004-12-16 · LEI
HERBALIFE LTD. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0B | $5.0B | $5.1B | $5.2B | $5.8B | $5.5B | $4.9B | $4.9B | $4.4B | $4.5B |
| Gross profit | $3.9B | $3.9B | $3.9B | $4.0B | $4.6B | $4.4B | $3.9B | $4.0B | $3.6B | $3.6B |
| SG&A expense | — | $1.9B | $1.9B | $1.8B | $2.0B | $2.1B | $1.9B | $2.0B | $1.8B | $2.0B |
| Operating income | $481.0M | $385.9M | $356.4M | $545.2M | $734.1M | $640.6M | $568.1M | $683.1M | $617.1M | $458.1M |
| Interest expense | $214.4M | $218.3M | $165.9M | $139.3M | $153.1M | $133.0M | $153.0M | $181.0M | $160.8M | $99.3M |
| Income tax | $47.3M | -$84.9M | $60.8M | $103.5M | $113.6M | $143.8M | $140.4M | $167.6M | $257.3M | $104.7M |
| Net income | $228.3M | $254.3M | $142.2M | $321.3M | $447.2M | $372.6M | $311.0M | $296.6M | $213.9M | $260.0M |
| EPS (diluted) | $2.20 | $2.50 | $1.42 | $3.23 | $4.13 | $2.77 | $2.20 | $1.98 | $1.29 | $1.51 |
| Operating cash flow | $333.3M | $285.4M | $357.5M | $352.5M | $460.3M | $628.6M | $457.5M | $648.4M | $590.8M | $367.3M |
| Free cash flow | $252.9M | $163.4M | $222.5M | $196.1M | $308.9M | $516.6M | $351.4M | $564.4M | $495.3M | $223.9M |
| Cash & equivalents | $353.1M | $415.3M | $575.2M | $508.0M | $601.5M | $1.0B | $839.4M | $1.2B | $1.3B | $844.0M |
| Inventory | $511.7M | $475.4M | $505.2M | $580.7M | $575.7M | $501.4M | $436.2M | $381.8M | $341.2M | $371.3M |
| Total assets | $2.8B | $2.7B | $2.8B | $2.7B | $2.8B | $3.1B | $2.7B | $2.8B | $2.9B | $2.6B |
| Total liabilities | $3.3B | $3.5B | $3.9B | $4.0B | $4.2B | $3.9B | $3.1B | $3.5B | $3.2B | $2.4B |
| Shareholders' equity | -$515.1M | -$801.1M | -$1.1B | -$1.3B | -$1.4B | -$856.1M | -$390.0M | -$723.4M | -$334.7M | $196.3M |
Growth · year-over-year · Revenue CAGR 1.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +0.9% | -1.4% | -2.7% | -10.3% | +4.7% | +13.6% | -0.3% | +10.5% | -1.4% | +0.4% |
| Net income growth | -10.2% | +78.8% | -55.7% | -28.2% | +20.0% | +19.8% | +4.9% | +38.7% | -17.7% | -23.3% |
| EPS growth | -12.0% | +76.1% | -56.0% | -21.8% | +49.1% | +25.9% | +11.1% | +53.5% | -14.6% | -23.9% |
| Free cash flow growth | +54.8% | -26.6% | +13.5% | -36.5% | -40.2% | +47.0% | -37.7% | +14.0% | +121.2% | -59.3% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.